|Mr. Steven L. Hoerter||Pres, CEO & Director||42.19k||N/A||1971|
|Mr. Thomas Patrick Kelly J.D.||Exec. VP, CFO & Treasurer||556k||N/A||1971|
|Mr. Daniel C. Martin||Chief Commercial Officer||807.17k||N/A||1975|
|Dr. Daniel L. Flynn||Exec. VP, Chief Scientific Officer & Founder||N/A||N/A||1955|
|Dr. Stephen B. Ruddy Ph.D.||Chief Technical Officer||N/A||N/A||1964|
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Deciphera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.